Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy

Aug 29 2017

• By Mandy Jackson

Handshake of businessmen

Related Content

Kite’s Axi-Cel CAR-T: No Adcomm, No Problem

Aug 11 2017

Novartis' CAR-T Poised For The Market After Unanimous FDA Adcomm Review

Jul 13 2017

Gilead Raises HCV Guidance Slightly, Still Mum On M&A

Jul 26 2017

Gilead's CEO Gives Glimpse Of Strategic Opportunities As HCV Sales Slide Continues

May 03 2017

Gilead wins Zydelig OK, but Pharmacyclics scores

Jul 24 2014

Kite First Off The Blocks For EU CAR-T Filing

Aug 01 2017

Related Companies

Gilead Sciences, Inc.

Kite Pharma, Inc.

Pharmasset, Inc.

Novartis AG

AbbVie Inc.

Johnson & Johnson

Pharmacyclics, Inc.

Additional Topics

Business Strategies Deals ImmunoOncology M & A Commercial BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window